Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach.

Kakwere H, Ingham ES, Allen R, Mahakian LM, Tam SM, Zhang H, Silvestrini MT, Lewis JS, Ferrara KW.

Bioconjug Chem. 2017 Nov 15;28(11):2756-2771. doi: 10.1021/acs.bioconjchem.7b00502. Epub 2017 Oct 13.

PMID:
28956907
2.

Docosahexaenoic acid (DHA) promotes immunogenic apoptosis in human multiple myeloma cells, induces autophagy and inhibits STAT3 in both tumor and dendritic cells.

D'Eliseo D, Di Renzo L, Santoni A, Velotti F.

Genes Cancer. 2017 Jan;8(1-2):426-437. doi: 10.18632/genesandcancer.131.

3.

Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.

Kortylewski M, Moreira D.

Cancer Immunol Immunother. 2017 Aug;66(8):979-988. doi: 10.1007/s00262-017-1966-2. Epub 2017 Feb 18. Review.

PMID:
28214929
4.

15-Deoxy-Δ(12,14)-prostaglandin J2 Induces Apoptosis and Upregulates SOCS3 in Human Thyroid Cancer Cells.

Trindade-da-Silva CA, Reis CF, Vecchi L, Napimoga MH, Sperandio M, Matias Colombo BF, Alves PT, Ward LS, Ueira-Vieira C, Goulart LR.

PPAR Res. 2016;2016:4106297. doi: 10.1155/2016/4106297. Epub 2016 Apr 17.

5.

CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation.

Kumar V, Cheng P, Condamine T, Mony S, Languino LR, McCaffrey JC, Hockstein N, Guarino M, Masters G, Penman E, Denstman F, Xu X, Altieri DC, Du H, Yan C, Gabrilovich DI.

Immunity. 2016 Feb 16;44(2):303-15. doi: 10.1016/j.immuni.2016.01.014.

6.

Smart CARs engineered for cancer immunotherapy.

Priceman SJ, Forman SJ, Brown CE.

Curr Opin Oncol. 2015 Nov;27(6):466-74. doi: 10.1097/CCO.0000000000000232. Review.

7.

Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice.

Pathria P, Gotthardt D, Prchal-Murphy M, Putz EM, Holcmann M, Schlederer M, Grabner B, Crncec I, Svinka J, Musteanu M, Hoffmann T, Filipits M, Berger W, Poli V, Kenner L, Bilban M, Casanova E, Müller M, Strobl B, Bayer E, Mohr T, Sexl V, Eferl R.

Oncoimmunology. 2015 Jan 22;4(4):e998529. eCollection 2015 Apr.

8.

STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis.

Yue C, Shen S, Deng J, Priceman SJ, Li W, Huang A, Yu H.

Cancer Immunol Res. 2015 Aug;3(8):864-870. doi: 10.1158/2326-6066.CIR-15-0014. Epub 2015 May 29.

9.

Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.

Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch E.

Cancer Immunol Res. 2015 Sep;3(9):1017-29. doi: 10.1158/2326-6066.CIR-14-0244. Epub 2015 May 26.

10.

STAT3 governs hyporesponsiveness and granzyme B-dependent suppressive capacity in human CD4+ T cells.

Schmetterer KG, Neunkirchner A, Wojta-Stremayr D, Leitner J, Steinberger P, Pickl WF.

FASEB J. 2015 Mar;29(3):759-71. doi: 10.1096/fj.14-257584. Epub 2014 Nov 14.

11.

CD8+ T-cell immunosurveillance constrains lymphoid premetastatic myeloid cell accumulation.

Zhang W, Zhang C, Li W, Deng J, Herrmann A, Priceman SJ, Liang W, Shen S, Pal SK, Hoon DSB, Yu H.

Eur J Immunol. 2015 Jan;45(1):71-81. doi: 10.1002/eji.201444467. Epub 2014 Nov 10.

12.

TLR9 is critical for glioma stem cell maintenance and targeting.

Herrmann A, Cherryholmes G, Schroeder A, Phallen J, Alizadeh D, Xin H, Wang T, Lee H, Lahtz C, Swiderski P, Armstrong B, Kowolik C, Gallia GL, Lim M, Brown C, Badie B, Forman S, Kortylewski M, Jove R, Yu H.

Cancer Res. 2014 Sep 15;74(18):5218-28. doi: 10.1158/0008-5472.CAN-14-1151. Epub 2014 Jul 21.

13.

Genetically modified T-cell therapy for osteosarcoma.

DeRenzo C, Gottschalk S.

Adv Exp Med Biol. 2014;804:323-40. doi: 10.1007/978-3-319-04843-7_18. Review.

14.

CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.

Herrmann A, Priceman SJ, Swiderski P, Kujawski M, Xin H, Cherryholmes GA, Zhang W, Zhang C, Lahtz C, Kowolik C, Forman SJ, Kortylewski M, Yu H.

J Clin Invest. 2014 Jul;124(7):2977-87. doi: 10.1172/JCI73174. Epub 2014 Jun 2. Erratum in: J Clin Invest. 2015 Jun;125(6):2547. Swiderski, Piotr [Added].

15.

PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.

Sabbatino F, Wang Y, Wang X, Flaherty KT, Yu L, Pepin D, Scognamiglio G, Pepe S, Kirkwood JM, Cooper ZA, Frederick DT, Wargo JA, Ferrone S, Ferrone CR.

Oncotarget. 2014 Apr 15;5(7):1926-41.

16.

Signal and depth enhancement for in vivo flow cytometer measurement of ear skin by optical clearing agents.

Ding Y, Wang J, Fan Z, Wei D, Shi R, Luo Q, Zhu D, Wei X.

Biomed Opt Express. 2013 Oct 17;4(11):2518-26. doi: 10.1364/BOE.4.002518. eCollection 2013.

17.

Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.

Hossain DM, Dos Santos C, Zhang Q, Kozlowska A, Liu H, Gao C, Moreira D, Swiderski P, Jozwiak A, Kline J, Forman S, Bhatia R, Kuo YH, Kortylewski M.

Blood. 2014 Jan 2;123(1):15-25. doi: 10.1182/blood-2013-07-517987. Epub 2013 Oct 29.

18.

Targeting the tumor microenvironment: JAK-STAT3 signaling.

Bournazou E, Bromberg J.

JAKSTAT. 2013 Apr 1;2(2):e23828. doi: 10.4161/jkst.23828. Review.

19.

STAT3 activation: A key factor in tumor immunoescape.

Rébé C, Végran F, Berger H, Ghiringhelli F.

JAKSTAT. 2013 Jan 1;2(1):e23010. doi: 10.4161/jkst.23010. Review.

20.

Regulation of adipose tissue T cell subsets by Stat3 is crucial for diet-induced obesity and insulin resistance.

Priceman SJ, Kujawski M, Shen S, Cherryholmes GA, Lee H, Zhang C, Kruper L, Mortimer J, Jove R, Riggs AD, Yu H.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13079-84. doi: 10.1073/pnas.1311557110. Epub 2013 Jul 22.

Supplemental Content

Support Center